KURN - Kuros Biosciences AG - Stock & Dividends

Kuros Biosciences AG is a biopharmaceutical company that focuses on developing and commercializing innovative solutions for tissue repair and bone regeneration globally.

The company operates through three distinct segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio, each playing a crucial role in its overall mission.

In the Medical Devices segment, Kuros Biosciences offers a range of advanced bone graft products, including MagnetOs Granules, which utilizes submicron needle-shaped NeedleGrip surface technology to promote bone growth. Additionally, the company provides MagnetOs Putty, a moldable solution for filling bony voids, and MagnetOs Easypack Putty, a ready-to-use mold for implantation in intervertebral disc spaces or posterolateral spine levels. Furthermore, Magnetos Flex Matrix is an open matrix bone graft designed for optimal bone regeneration.

In the Pharmaceuticals segment, Kuros Biosciences is developing a pipeline of Fibrin-PTH products, including KUR-111 and KUR-113, which are currently in Phase 2b clinical trials for trauma indications. KUR-113 is also being evaluated in a Phase 2a clinical trial for spinal indications, demonstrating the company's commitment to addressing a range of unmet medical needs.

Founded in 2016, Kuros Biosciences is headquartered in Schlieren, Switzerland, and is dedicated to improving patient outcomes through its innovative tissue repair and bone regeneration solutions. For more information, visit the company's website at https://www.kuros.ch.